SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwired - June 21, 2013) -
Election of Vicente Anido, Jr. to Nicox's Board of Directors
Vaughn Kailian re-elected Director
June 21, 2013.
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announced the election of
Anido, Jr., PhD., to the Company's Board of Directors for a period of four
years. Dr. Anido is a highly experienced and respected leader in the
ophthalmology sector and most recently served as President and Chief
Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb.
The Company also announced that Vaughn Kailian, Managing Director at MPM
and former President & CEO of COR Therapeutics, has been re-elected as a
of the Board of Directors for a period of four years. Bengt Samuelsson and
Jorgen Buus Lassen have retired from the Board due to their reaching the
limit set out in the Company's by-laws.
"I am honoured to join Nicox's Board of Directors. The Company already has
number of promising assets and a sound strategy to become an international
innovative ophthalmic company. I look forward to sharing my experience and
contributing to the future growth of the business", said Vicente Anido.
"We are pleased to welcome Vicente Anido as a member of the Nicox Board of
Directors and would also like to thank Vaughn Kailian for his continued
for Nicox as a Board member" said Michele Garufi, Chief Executive Officer
Nicox. "We look forward to their unique contributions as we continue to
transform Nicox into a leading international ophthalmology company."
"On behalf of the Board, Nicox's management and its employees I would like
express my sincere gratitude to Bengt Samuelsson and Jorgen Buus Lassen.
guidance and support has been of great value to the Company over the past
fifteen years, particularly during our current period of transition."
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new
international player in the ophthalmic market by building a
portfolio of innovative therapies and diagnostic tools. With a
scientific, business development and commercial expertise, the Nicox
focused on developing and marketing novel pharmaceuticals and diagnostic
that can help people to enhance their sight. In the United States, Nicox
AdenoPlus(®), a test for the differential diagnosis of acute
in-licensed from RPS®.
The Company's pipeline includes latanoprostene bunod, a novel
drug-candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D
developed in collaboration with Bausch + Lomb for the potential treatment
glaucoma and ocular hypertension. Further NO-donating compounds are under
development in non-ophthalmic indications, notably through partners,
Merck (known as MSD outside the United States and Canada).
Nicox S.A. is headquartered in France and is listed on Euronext
(Compartment B: Small Caps). For more information please visit
This press release contains certain forward-looking statements. Although
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's
presented in the 4th chapter of the « Document de référence,
annuel et rapport de gestion 2012 » filed with the French
Autorité des Marchés
Financiers (AMF) on March 22, 2013 and available on Nicox's website
(www.nicox.com) and on the AMF's website (www.amf-france.org).
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE